# A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis

> **NCT04697056** · PHASE2 · TERMINATED · sponsor: **Vanda Pharmaceuticals** · enrollment: 5 (actual)

## Conditions studied

- Ichthyosis

## Interventions

- **DRUG:** Imsidolimab
- **BIOLOGICAL:** placebo

## Key facts

- **NCT ID:** NCT04697056
- **Lead sponsor:** Vanda Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-25
- **Primary completion:** 2021-11-19
- **Final completion:** 2021-11-19
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Administrative Reason
- **Last updated:** 2025-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04697056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04697056, "A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04697056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*